Takara Bio Inc is primarily active in the life sciences industry. This Japanese company specializes in the development and manufacture of biotechnology products, including genomic research tools, reagents, and systems for areas such as genetic engineering, stem cell research, and diagnostics. Takara Bio Inc's innovative solutions and advanced technologies have made significant contributions to various fields of life sciences, including academic research, pharmaceutical development, and agricultural biotechnology. As a leader in the industry, Takara Bio Inc continuously strives to advance scientific knowledge and provide cutting-edge solutions for the global life sciences community.

The main competitors of Takara Bio Inc in the market are Thermo Fisher Scientific, Bio-Rad Laboratories, and QIAGEN.

Takara Bio Inc is a leading biotechnology company based in Japan. Established in 1967, the company has a rich history and a strong background in the field. Takara Bio specializes in the development and manufacture of a wide range of innovative products and solutions for the life sciences industry. With a focus on advancing research and improving human health, Takara Bio has become synonymous with reliability and cutting-edge technology. Through its dedication to quality and customer satisfaction, the company has gained a global reputation as a trusted provider of biotechnology solutions.

Takara Bio Inc, a leading biotechnology company, has achieved several significant milestones. They developed and commercialized various innovative products and technologies for life science research, including PCR and DNA sequencing systems. Takara Bio Inc played a pivotal role in advancing genetic engineering and molecular biology techniques worldwide. Additionally, they developed advanced stem cell technologies and contributed to significant breakthroughs in regenerative medicine. Moreover, the company successfully expanded its global presence by establishing subsidiaries and collaborations in various regions. With its continuous commitment to innovation and research, Takara Bio Inc remains at the forefront of the biotechnology industry, providing valuable solutions to researchers and scientists worldwide.

Takara Bio Inc is primarily present in Japan, with its headquarters located in Kusatsu, Shiga. Apart from its domestic presence, the company also maintains a global presence with operations and subsidiaries in various countries and regions including the United States, Europe, China, and other Asian countries. Takara Bio Inc is a leading biotechnology company specializing in the development and distribution of life science research reagents, gene therapy products, and molecular diagnostics. With its extensive global reach, Takara Bio Inc continues to provide innovative solutions and contribute to advancements in the fields of genomics, stem cell research, and personalized medicine.

Takara Bio Inc represents values of innovation, dedication, and collaboration in the field of biotechnology. With their corporate philosophy centered on contributing to society through the development of advanced technologies, Takara Bio Inc focuses on improving the quality of life and healthcare. The company aims to create value by delivering cutting-edge solutions and products that cater to diverse research needs, ranging from genetic analysis to regenerative medicine. Takara Bio Inc prioritizes customer satisfaction, sustainability, and responsible business practices, ensuring sustainable growth and development in the biotechnology industry.

Analysts currently set an average price target of 1,063.35 JPY for the Takara Bio stock (median: 800.70 JPY), implying -7.0 % versus the latest price. The consensus is based on 8 analyst ratings.

Takara Bio Analyst Price Targets 2026

8 analysts currently rate the Takara Bio stock: 4 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Takara Bio to generate revenue of 49.46 B JPY and earnings per share of 39.20 JPY.

Takara Bio Analyst Price Targets 2026

Converted at the current exchange rate, the Takara Bio share trades at 6.32 EUR (1,144.00 JPY).

The Takara Bio share (4974.T) is listed on 3 stock exchanges, including: Frankfurt (TF2.F), München (TF2.MU).

Takara Bio Inc is a leading company in the field of biotechnological research and development. The company specializes in the manufacturing and marketing of high-quality biological reagents and instruments that support a variety of research applications. The business model of Takara Bio Inc is based on providing products and services that assist researchers and scientific laboratories in carrying out their critical workflows. The company offers a wide range of reagents and instruments that focus on various applications such as gene expression, genotyping, proteome analysis, and cell culture. These products are sold worldwide to a variety of customers including pharmaceutical, biotech, and diagnostic companies, as well as public and private research institutions. Takara Bio Inc also has a research and development department that develops new and innovative products to provide solutions to customers and researchers. One such innovation is the SmartChip PCR system, a fully automated instrument that processes multiple samples simultaneously and is used to analyze gene expression profiles on a single chip. Another important area of focus for Takara Bio Inc is the manufacturing of mRNA-based therapeutics, which are used to combat diseases such as cancer. The company has already achieved significant success in this regard and has formed partnerships with other companies and research institutions to further advance. Takara Bio Inc divides its business model into three main divisions. The first division deals with the sale of reagents and instruments for genomic research and cellular analysis. Here, the company offers a wide range of reagents and kits to support DNA purification, PCR products, nanopore sequencing, amplification, genotyping and labeling, as well as plasmid minipreps and RNA isolation. The second division is the therapeutics division, which focuses on mRNA-based therapeutics and customized therapeutic vaccines to keep customers at the forefront of disease fighting in the biotech industry and clinical research. Takara Bio Inc has produced innovative methods for developing vaccines against cancer and other diseases. The third division is the service-oriented application technology, which assists customers in overcoming complex research challenges. The services include customized and technically sophisticated programs such as RNA sequencing, FACS assays, and ChIP sequencing. In summary, Takara Bio Inc is a company that focuses on biotechnological research and development. The business model of Takara Bio Inc includes the manufacturing and marketing of biological reagents and instruments that can be used in both basic research and clinical research and diagnostics. The three main divisions of Takara Bio Inc are the sale of reagents and instruments for genomic research and cellular analysis, the development of mRNA-based therapeutics, and services for customized application programs. With a strong focus on quality and innovation, Takara Bio Inc drives biotechnological research and development and is a leading company in this field.

The expected revenue of Takara Bio is 49.46 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Takara Bio is 4.72 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Takara Bio is currently 29.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Takara Bio stock.

The price-to-sales ratio (P/S) of Takara Bio is currently 2.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Takara Bio stock.

The Eulerpool Quality Score for Takara Bio is 3/10.

The ISIN of Takara Bio is JP3460200003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Takara Bio is A0DNGL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Takara Bio is 4974.T. The ticker symbol is used to trade Takara Bio shares on the stock exchange.

Over the past 12 months, Takara Bio paid a dividend of 17.00 JPY . This corresponds to a dividend yield of about 1.49 %. For the coming 12 months, Takara Bio is expected to pay a dividend of 34.00 JPY.

The current dividend yield of Takara Bio is 1.49 %.

Takara Bio pays a dividend, distributed in the months of , , , .

Takara Bio paid dividends every year for the past 14 years.

For the upcoming 12 months, dividends amounting to 34.00 JPY are expected. This corresponds to a dividend yield of 2.97 %.

Takara Bio is assigned to the 'Health' sector.

To receive the latest dividend of Takara Bio from amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Takara Bio distributed 42 JPY as dividends.

The dividends of Takara Bio are distributed in JPY.